Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis
Jonathan Q Tran,1 Ahmed A Othman,2,3 Alvydas Mikulskis,4 Paul Wolstencroft,5 Jacob Elkins6 1Clinical Pharmacology, Biogen, Cambridge, MA, USA; 2Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, USA; 3Faculty of Pharmacy, Cairo University, Cairo, Egypt; 4Global Biomarker Disc...
Enregistré dans:
Auteurs principaux: | Tran JQ, Othman AA, Mikulskis A, Wolstencroft P, Elkins J |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2016
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/825bb9c9b25d4e2c8e4a5b15221ed180 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
par: Cohan S
Publié: (2016) -
Assessing Lumbar Plexus and Sciatic Nerve Damage in Relapsing-Remitting Multiple Sclerosis Using Magnetisation Transfer Ratio
par: Ratthaporn Boonsuth, et autres
Publié: (2021) -
Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing–Remitting from Secondary Progressive Multiple Sclerosis. A Review
par: Sylwia Pietrasik, et autres
Publié: (2021) -
Promising Effects of Vitex Agnus-Castus on Quality of Life and Sexual Function in Premenopausal Relapsing Remitting Multiple Sclerosis Patients
par: Sara Rahgooy, et autres
Publié: (2020) -
Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study
par: Konrad Rejdak, et autres
Publié: (2021)